- Tempus | AI-enabled precision medicine
Tempus has built the world’s largest library of clinical molecular data and an operating system to make that data accessible and useful, starting with cancer
- Tempus AI - Wikipedia
Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, [5] for oncology, cardiology, radiology, and depression The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM " [6][7]
- Tempus - compcancercare. com
TEMPUS® is a technology company that has built the world's largest library of clinical and molecular data and an operating system to make that information accessible and useful for patients, physicians and researchers
- Tempus AIs Data Business Is Expanding and Adding to Revenues . . .
Tempus AI ’s ( TEM Quick Quote TEM - Free Report) third-quarter 2025 results highlight the growing strategic importance of its Insights and Data Services business, which is emerging as a high
- What Does Tempus AI Actually Do? Unveiling the AI Revolution . . .
In 2015, with a vision to revolutionize how doctors use data in clinical settings, Lefkofsky established Tempus The initial aim was to create a system where doctors could access a comprehensive, real-time view of a patient's medical history, including genomic, clinical, and imaging data
- Tempus | SoftBank Group Corp.
Launched in the United States in 2015, Tempus is now one of the largest sequencers of cancer patients in the world Having built its platform for oncology, it has expanded to neuropsychiatry, cardiology, infectious disease, and radiology
- Why Tempus AI Stock Soared This Week | The Motley Fool
A well-known analyst believes this AI healthcare stock has room to soar According to data provided by S P Global Market Intelligence, Tempus AI stock rose 10 9% from the end of last Friday's
- Providers - Tempus
For clinicians associated with advanced research initiatives, Tempus provides next-generation genomic profiling, biological organoid modeling, image pattern AI recognition, and a range of clinical trial and research collaborations
|